EMCDDA founding regulation
The original EMCDDA founding regulation, which dates from 1993, was recast in December 2006, with the aim of helping the agency better respond to new challenges in the field of drugs. At the bottom of this page, you will find links to PDFs of:
- the recast regulation of December 2006
- the original founding regulation of 1993
The rest of this page gives a brief overview of the changes introduced by the recast regulation.
Clear definition of the functions of the Reitox national focal points
New composition and selection procedure of the Scientific Committee
At most 15 members will be appointed by the Management Board after a call for expressions of Interest published in the Official journal. The new Regulation also takes into account the new role in the Council Decision of 10 May 2005 on information exchange, risk assessment and control of new psychoactive substances.
A new body: the Executive Committee
The Executive Committee‘s main role is to prepare the decisions of the Management Board.
New rule for evaluation reports
An external evaluation of the Centre's work, including the Reitox system, is to be conducted every six years. On the basis of this evaluation, the Commission may, if appropriate, present proposals with a view to amending the EMCDDA Regulation.
New role and responsibilities of the Director
These have been adjusted according to Commission guidelines concerning Community agencies directors. Director and Chairperson of the Management Board may also be asked for hearing before the European Parliament on any subject related to the Centre’s activities. The Director is responsible for assessing the Centre’s work.
New rule for the Management Board activities and the role of vice chairperson is created
New priority areas of activity
These are: monitoring the state of the drugs problem and emerging trends; monitoring the solutions applied to drug related problems; assessing the risks of new psychoactive substances and maintaining a rapid information system; and developing tools and instruments to facilitate the Member States' and the Commission's monitoring and evaluation of their respective drugs policies.
- The EMCDDA's collection, registration and analysis work must also cover data on emerging trends in poly drug use, including the combined use of licit and illicit psychoactive substances, but also information on best practices in the Member States and the exchange of such practices among them
- The EMCDDA is now also required to develop tools and instruments to facilitate the Member States' and the Commission's monitoring and evaluation of their respective drugs policies and strategies
- Lastly, the scope of the Centre's technical assistance is extended to certain non-Community countries such as the candidates for EU accession or the countries of the Western Balkans